KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103.

Authors

Maarten Niemantsverdriet¹, Ed Schuuring¹, Arja Ter Elst¹, Antonie J van der Wekken², Leon C van Kempen¹, Anke van den Berg¹, Harry J M Groen³

Affiliations

¹ Department of Pathology, Laboratory for Molecular Pathology, University Medical Center Groningen, Groningen, The Netherlands.
² Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands.
³ Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: h.j.m.groen@umcg.nl.

PMID: 30467046
DOI: 10.1016/j.jtho.2018.07.103

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm / genetics*
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology
MAP Kinase Kinase 1 / antagonists & inhibitors*
Middle Aged
Mutation*
Prognosis
Protein Kinase Inhibitors / pharmacology*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins p21(ras) / genetics*

Substances

KRAS protein, human
Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase 1
MAP2K1 protein, human
Proto-Oncogene Proteins p21(ras)